All News
Dr Richard Furie-> Obinutuzumab for proliferative #lupus nephritis
-Compared to rituximab, has more B-cell depletion in tissue and #SLE patients
-Meaningful benefits over SOC alone on renal response through week 104.
-Phase 3 REGENCY pending.
#ACR20
#ACRambassador
#Rheumatology https://t.co/aPi1yueAiV
Mohammad A. Ursani MD, RhMSUS DrMAUrsani ( View Tweet)
Can’t a clinician usually differentiate dermatomysitis skin changes from cutaneous lupus and if not would it affect your Rx of the skin involvement - HCQ, MMF, MTX, Aza & topicals. IL18 sigatures. But I get it. Impt for pathogenesis! @RheumNow #ACR2020 @CRASCRRheum https://t.co/RJh7fEVo4O
Janet Pope Janetbirdope ( View Tweet)
@andreafava representing @jhrheumatology @HopkinsBayview at plenary session! Urine proteomic biomarkers can revolutionize the way we see LN, and decrease need for renal Bx #Acr20 @RheumNow Abst#0936 https://t.co/zGoqmBPddT
Eric Dein ejdein1 ( View Tweet)
Can we use urine testing ( and all the cells, proteins, complements, DNA, rna) to predict LN response? Plenary II @SalemAlmaani @BradRovin @RheumNow #ACR20 @OSUWexMed
alexa meara lexmeara ( View Tweet)
Great talk #ACR20 Integrating bulk and single-cell RNA-sequencing @Kahlenberglab identifies clinically actionable 5-gene signatures that can effectively differentiate DM from cutaneous lupus lesions. @RheumNow @UMIntMed Also out in @JCI_insight https://t.co/uYS6OJH0Hf https://t.co/KR0wwDb5BK
Yu (Ray) Zuo RayZuoMD ( View Tweet)
50% use septra/bactrim in SLE if immunesuppressed. I don’t use it unless if frequent serious infections or bad lungs as I am not convinced about the risk of PCP/PJP v risk of septra with adverse rxns in SLE. I await an admin database to give me the data @RheumNow #ACR20 https://t.co/3s2S9fIUVe
Janet Pope Janetbirdope ( View Tweet)
Dr. Aggarwal Abs#0955 showed efficacy of IVIG in tx of Dermatomyositis.
How/when do you use IVIG for tx of DM?
@RheumNow #ACR20
Robert B Chao, MD doctorRBC ( View Tweet)
Efficacy of IVIG in Dermatomyositis Treatment
1st Placebo controlled RCT
1️⃣79% responder by total improvement score vs. 44%
2️⃣Efficacy sustained thru wk 40
3️⃣6% serious AE - thromboembolic event
@RheumNow #ACR20 Abs#0955 #ACRbest https://t.co/715h1UkZ9X
Robert B Chao, MD doctorRBC ( View Tweet)
ProDERM study:10% IVIG is effective and safe in pts with DM. First large PBO-controlled, randomized ph 3 trial. @RheumNow #ACR20 abs0995 #ACRbest https://t.co/aJyASaAMlJ
sheila RHEUMarampa ( View Tweet)
#HCQ assoc. w/ ↓platelet activity & ↑vascular health in #SLE:
- 132 patients, 108 on HCQ
- Ex-vivo expts show ↓platelet aggregation & downregulation of platelet functional pathways
- HCQ may improve vascular health in SLE
Abs#0870 #ACR20 @RheumNow
https://t.co/ST9n2HGyhM
Mrinalini Dey DrMiniDey ( View Tweet)
Data from MUSE & TULIP trials of #anifrolumab in #SLE show increased risk of #herpeszoster when compared to placebo. Most HZ events mild-moderate, cutaneous and resolved without discontinuation of drug.
#RheumTwitter #lupus
Abs#0849 #ACR20 @RheumNow
https://t.co/8a6OcZmOso
Mrinalini Dey DrMiniDey ( View Tweet)
HCQ Not Associated with QTc Length in SLE and RA Patients: Dr. Janet Pope @Janetbirdope #ACR20
https://t.co/zPIaFIiqr5 https://t.co/Wk8YQpIpo7
Links:
Dr. John Cush RheumNow ( View Tweet)
Congrats to Dr S Izuka a clinical Rheumatolgy fellow for making a press release. Looking forward to full presentation next week. We published SLE pts had more adverse drug reactions than RA so I try to avoid sulfa drugs in SLE JRheum 2003;30:480-4 #ACR2020 https://t.co/spr6FsS1xg
Janet Pope Janetbirdope ( View Tweet)
Among a 402 pt PSS cohort, 10% fmet 2019 EULAR/ACR SLE Criteria. SSc-SLE overlap pts more likely to be female, AfricanAmerican, limited cut.SSc, U1RNP and have similar rates of severe SSc-specific organ damage /mortality. #ACR20 Abstr#0401 https://t.co/CVcFyx9AxS https://t.co/3SAKZ9CZGS
Dr. John Cush RheumNow ( View Tweet)
Olmstead County (Mayo) population study shows 47 lupus nephritis (LN) pts betw 1976-2018. Incidence doubled from 1980s (0.6 per 100K) to 2018 (1.2/100K); with women of childbearing age as the most affected group. #ACR20 Abstr#0274 https://t.co/uhAMd0EtJl
Dr. John Cush RheumNow ( View Tweet)
Dr. C Mohan @UTSWNews #ACR20 @rheumnow reviews IFN in SLE:
👉Diff't IFN assc w/diff't lupus manifestions
👉⬆️stim endosomal DNA/RNA sensors RLR7,8,9 may drive SLE
👉TLR7 & 9 in B cells impt for germinal ctrs & Ab prod’n
👉TLR7 is X-linked
👉IFNsig not track w/dz activity https://t.co/3KK3UvH8Ka
k dao KDAO2011 ( View Tweet)
Year in review @JYazdanyMD take home points from 2 key positive trials (finally!) in SLE this year #ACR20 @RheumNow https://t.co/74SVwNavPK
Richard Conway RichardPAConway ( View Tweet)
#ACR20 Abstr#0433 #PlenaryACR Georgia SLE registry 336 pts ⬆️stroke/isch heart dz with:
👉3X stroke risk and 24X IHD risk for black pts
👉predictors stroke: black race, DLE, renal dz
👉predictors IHD: age>65, black race, neuro & immuno d/o (e.g, APAs)
@RheumNow https://t.co/u6Ky7r0FYF
k dao KDAO2011 ( View Tweet)
Plenary session 1 no#2F011 #ACR20 @rheumnow
Black #SLE patients have a 3 fold higher stroke and 24 fold higher Ishemic Heart Disease risk! https://t.co/AYtiXk7pDa
Bella Mehta bella_mehta ( View Tweet)
#hydroxychloroquine is not a ‘cutie’ drug. E Park et al showed that HCQ does not increase QT interval in RA & SLE patients including if on other meds that may affect QT but known heart disease excluded from study #ACR20 #ACR2020 @RheumNow abstr#432 @CRASCRRheum https://t.co/FGVPknmj5q
Janet Pope Janetbirdope ( View Tweet)
